CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
63 hedge funds and large institutions have $118M invested in CTI BioPharma Corp. (DE) Common Stock in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 11 closing their positions.
88% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $570K
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
13% more funds holding
Funds holding: 56 → 63 (+7)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
26% less capital invested
Capital invested by funds: $160M → $118M (-$41.3M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$3.63M |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$3.03M |
| 3 |
LPC
Lion Point Capital
New York
|
+$2.99M |
| 4 |
BlackRock
New York
|
+$2.21M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$22.2M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$6.12M |
| 3 |
ACM
Altium Capital Management
New York
|
-$2.76M |
| 4 |
Two Sigma Investments
New York
|
-$1.75M |
| 5 |
Two Sigma Advisers
New York
|
-$1.28M |
CTIC Hedge Fund Activity: Q4 2021 in Review
63 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2021, worth a combined $118M — down 26% from $160M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CTIC positions and 11 closed out — a net gain of 8 holders — while 17 added to existing stakes and 16 trimmed.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $3.63M. The largest seller was OrbiMed, exiting entirely with an estimated $22.2M sold.
- 63 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2021, up from 56 in Q3 2021.
- Funds reported $118M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2021, down 26% quarter-over-quarter.
- 19 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2021 and 11 closed out, a net change of +8 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2021 was Silverarc Capital Management, an estimated $3.63M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2021 was OrbiMed, an estimated $22.2M sold.
Based on aggregated 13F filings for Q4 2021.